SOURCE: Plandai Biotechnology, Inc.

Plandai Biotechnology, Inc.

April 14, 2015 08:30 ET

New Video Documents Plandai Biotechnology's $20 Million Operation at Senteeko Tea Estate

NEW YORK, NY--(Marketwired - April 14, 2015) - Plandaí Biotechnology (OTCQB: PLPL) and its operations at the Senteeko tea estate in South Africa are the subject of a newly released video.  Stock Market Media Group, a content development investment relations firm, spent a week in South Africa with a camera crew from Bay Colony Media documenting the company's story, and announced today that the documentary is now available.   

The video can be seen at www.stockmarketmediagroup.com/media.

In the documentary, viewers will go inside the gates of the Senteeko tea estate and see for themselves the beauty that makes up the property's 8,000 acres.  The video also highlights the many fields of tea that produce the raw material that Plandaí uses to make its highly bioavailable green tea extract, Phytofare® Catechin Complex.

Viewers will visit North West University's Potchefstroom Campus and learn first-hand, from the scientists there who put the company's green tea extract through human clinical trials, just what bioavailability is and why getting the product into the bloodstream and keeping it there is so important to end users of Plandaí's product or of any nutraceutical product for that matter. 

The Head of the University's Preclinical Drug Development Platform, Prof. Anne Grobler, explains Plandaí's incredible clinical trial results, and we learn more about the Pheroid technology that the company will employ to deliver its extracts deeper into the body on the cellular level.

While at Senteeko viewers will go inside the company's 30,000 square foot production facility and watch the staff at the factory turn tea leaves into a vibrant, rich emerald green colored green tea extract.  In the video, both the company's CEO and the V.P. of Sales and Marketing discuss Senteeko's early days, the tea estate today, the production process, Plandaí's sales and marketing efforts and its future plans with other extracts.

The Plandaí story can be seen at www.stockmarketmediagroup.com/media.

We would like to thank Bay Colony Media (www.baycolonymedia.com), located in the Greater Boston area, for their hard work and dedication to helping Stock Market Media Group tell the Plandaí Biotechnology story.

About Stock Market Media Group

SMMG is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles. We may from time to time include our own opinions about our featured companies, their businesses, markets and opportunities. Any opinions we may offer are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers and viewers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any company are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: http://www.sec.gov. We also recommend as a general rule, that before investing in any securities you consult with a professional financial planner or advisor.

We are not a registered broker, dealer, analyst, or adviser. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications are not a recommendation to buy or sell a security.

Section 17(b) of the 1933 Securities and Exchange Act requires publishers who distribute information about publicly traded securities for compensation, to disclose who paid them, the amount, and the type of payment.  In order to be in full compliance with the Securities Act of 1933, Section 17(b), we are disclosing that SMMG is compensated $3,500 per month by Plandai Biotechnology for content development. Previously, SMMG was compensated for similar content by a third party which occurred from April 2013 through June 2014. During that period, SMMG received approximately $55,000 for its content. Neither SMMG nor anyone associated with it owns shares in PLPL.

For more information: www.stockmarketmediagroup.com.

Contact Information